Revenues were $0.00. atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. 0. About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Be cautious prior to entering such a volatile market. With these data, from the interim analysis of the ongoing Phase 2a trial, we are encouraged to accelerate the overall development of RL-007 for CIAS," said Matthew Pando, PhD, CEO and Co-Founder of Recognify Life Science . I FUCKIN AM! Summary of all time highs, changes and price drops for Atai Life Sciences; Historical stock prices; Current Share Price: US$17.00: 52 Week High: US$22.91: 52 Week Low: US$12.12: Beta: 0: 1 Month Change: 22.66%: 3 Month Change: 16.28%: 1 Year Change: n/a: 3 Year Change: n/a: 5 Year Change: n/a: Change since IPO-12.60% Deciphera Pharmaceuticals Stock Forecast, Price & News $8.07-0.28 (-3.35%) (As of 11/26/2021 04:00 PM ET) Add. The current price level -28.33% lower than the highest price of $22.91 marked by the stock while trading over the past 52-weeks, whereas it is 25.06% higher than the lowest price of $13.13 the company dropped to over past 52-weeks. View atai Life Sciences N.V. ATAI investment & stock information. ATAI's earnings per share (EPS) was $-0.37, missing the consensus analysts forecast of $-0.18 by -102.19%. Atai Life Sciences N.V. (NASDAQ: ATAI) Shares Are Set To Rise By 2021 Atai Life Sciences N.V. (NASDAQ:ATAI) shares, rose in value on Friday, 11/26/21, with the stock price down by -1.06% to the previous days close as 9 analysts offering 12-month price targets in the last 3 months for ATAI Life Sciences evaluate the company at an average price target of $27.89 with a high of $45.00 and a low of $19.00. About atai Life Sciences. Investors should keep them on their radars as they have massive long-term potential. As an investor, you can get an idea of where the stock is trending by the forecast and beta. Norms and regulations in society can change in the span of a few generations. life ; EU Commission raises 2021 euro zone growth forecast, sees strong 2022; Global shares are mixed as Inflation, and the possible central bank reaction to it, remains a dominant theme in markets. The number of outstanding shares for ATAI Life Sciences NV is 154820000. Based on our forecasts, a long-term increase is expected, the "ATAI" stock price prognosis for 2026-11-13 is 82.724 USD. ATAI Life Sciences B.V. ( ATAI) intends to raise $200 million from the sale of its common stock in an IPO, according to an amended registration statement. ATAI Life Sciences NV's share price could stay at $31.00 by Nov 22, 2022. Thinking about investing in Atai Life Sciences N.V. because of the upcoming earnings date annual report or stock price forecast? Atai Life Sciences N.V. (NASDAQ:ATAI)s beta value is holding at 0, while the average true range (ATR) indicator is currently reading 1.21. With ATAI Life Sciences NV stock trading at $13.99 per share, the total value of ATAI Life Sciences NV stock (market capitalization) is $2.17B. A stock is considered to be oversold if the RSI reading falls below 30. September 15, 2021. Atai Life Sciences N.V. (NASDAQ: ATAI) Shares Are Set To Rise By 2021 Atai Life Sciences N.V. (NASDAQ:ATAI) shares, rose in value on Friday, 11/26/21, with the stock price down by -1.06% to the previous days close as Reinforces COMPASS as highly complementary to atais diversified approach to innovation in mental health On average, they anticipate Atai Life Sciences' share price to reach $29.33 in the next year. atai Life Sciences (Nasdaq: ATAI) (atai), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today. Earnings for Atai Life Sciences are expected to decrease in the coming year, from ($0.60) to ($1.16) per share. Butterfly Network, Inc. (NYSE: BFLY ) dipped 12.6% Over the short-term, Psychedelic Stock Watch sees the best investment opportunities from this IPO in other psychedelic stocks. atai Impact is committed to advancing education, expanding access and supporting the wider ecosystem of mental health care. October 23, 2021. Business. The company is aiming to transform the treatment of mental health disorders. 13 brokerages have issued 12-month target prices for Atai Life Sciences' shares. Peter Thiels atai Life Sciences led a wave of biotechs to the public equities markets on Friday. Atai Life Sciences (NASDAQ: ATAI) will soon go public, and its one of the most anticipated IPOs of the year. Atai Life Sciences N.V. (ATAI) Analyst Forecast Next 12 months MEAN $31.57 +111.60% HIGH $45.00 +201.61% LOW $19.00 +27.35% Current Price $14.92 52-week High $22.91 52-week Low $12.12 ATAI Price, Volume, Earnings, and Dividend Date STOCK. 1,239 Followers, 304 Following, 12 Posts - See Instagram photos and videos from abdou now online (@abdoualittlebit) ATAI Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Atai Life Sciences, the Peter Thiel-backed start-up that wants to use psychedelic drugs to treat mental health conditions, has increased its stake in fellow drug developer Compass Pathways. The stock has a consensus analyst rating of "Buy." post. The historical data and Price History for Atai Life Sciences N.V. (ATAI) with Intraday, Daily, Weekly, Monthly, and Quarterly data available for download. Now that you know more about ATAI Life Sciences NV stands, lets learn more about the future of the company. ATAI Life Sciences N.V. ATAI, +3.19% has set terms for its initial public offering, in which the Germany-based biopharmaceutical company focused on 0. Our overall hedge fund sentiment score for ATAI is 44.5. We would like to show you a description here but the site wont allow us. There has been speculation that ATAIs IPO might come sooner than expected. 01, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai") today announced that it has observed encouraging interim data from the first 8-patient cohort of its Phase 2a trial, demonstrating potential ATAI Life Sciences N.V. Stock Price Forecast, "ATAI" Predictons for2021 About ATAI Life Sciences N.V. C/O MINDSPACE KRAUSENSTRASSE 9-10, BERLIN, 10117, Germany +49 8921539035 https://www.atai.life. Since Atai Life Sciences is only going public, we dont have any forecast for the stock. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. ATAI Previous Earnings Date & Report Recap: Jun 2021 (FQ) Atai Life Sciences's previous earnings date was Aug 16, 2021 for its fiscal quarter ended Jun 30, 2021. Following our IPO in June, we continue to see positive momentum. Currently consolidating at $2.24 a share, Id like to see the stock test its prior high. ATAI Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. The overall trend of the equity (stock) appears to be negative (considering since Mid 2011). BC Craft works with local artists cross-sector and remains fervently committed to keeping the art, technique, and purity of their pursuit. Forecast & Beta. Company profile page for ATAI Life Sciences NV including stock price, company news, press releases, executives, board members, and contact information atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. Forecast & Beta. View the latest ratings for ATAI. ATAI Stock Predictions, Articles, and Atai Life Sciences N.V. News From InvestorPlace From the Web Benzinga's Top Ratings Upgrades, Downgrades For November 11, Provide the latest ATAI Life Sciences NV(ATAI) market data, including prices, cycle charts, basic information and real-time news information, financial analysis, company introduction, dividends and dividend information, you can also use Moomoo to open an account to trade ATAI Life Sciences NV stockswe will provide investors with reference decision data. The Companys Shares also have DTC Eligibility and are Listed on the Frankfurt Stock Exchange under the 97X Stock SymbolVANCOUVER, British Columbia, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (Irwin or the Company), a household name and best-in-class herbal supplement formulator since 1994 that is leveraging its Beta is calculated using regression analysis. The company has an average price target of $30.6 with a ATAI is planning to offer their shares to the public in an IPO that expects to raise $100 million. Your current $100 investment may be up to $710.08 in 2026. The atai RL-007 trials are being conducted by Recognify Life Sciences, an atai Life Sciences platform company. " The last closing price of the ATAI Life Sciences N.V. share was $13.50 and has changed by 4.09% since the penultimate trading day. The Peter Thiel-backed healthcare and psychedelics company, which has already raised $362 million from private investors, is about to Michael Auerbach, founder of Subversive Capital, which has invested in psychedelic drug companies, said they have the potential to develop multibillion-dollar drugs. 11/15 12:02 Mynaric stock pops 33% intraday after Christian Angermayer-backed laser firm stages IPO In last trading session, Atai Life Sciences N.V. (NASDAQ:ATAI) saw 0.36 million shares changing hands with its beta currently measuring 0. ATAI Life Sciences market cap is $2.3 b.. View ATAI Life Sciences stock / share price, financial statements, key ratios and more at Craft. Below is The stock's open price was 14.85.Atai Life has less than a 13 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. BERLIN, June 11, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (atai), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the commencement of a proposed underwritten initial public offering of 14,286,000 of its common shares. atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenxs Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.--Annual Dividend/Yield. Hello Successful Traders, The stock (ATAI) has presented a modest growth in price value throughout the last couple of hours. Get the latest atai Life Sciences N.V. ATAI detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. On average, Wall Street analysts predict that . ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. ATAI Life Sciences NV has fallen lower in 7 of those 13 years over the subsequent 52 week period, corresponding to a historical accuracy of 70 % ATAI Life Sciences is poised to become the new industry leader among public companies when it commences trading as a new psychedelic stock. It is expected that more than 50% of the U.S. population will be diagnosed with a mental health disorder at some point in their lifetime, with increasing incidence ascribed to the COVID-19 pandemic. 9 analysts offering 12-month price targets in the last 3 months for ATAI Life Sciences evaluate the company at an average price target of $27.89 with a high of $45.00 and a low of $19.00. China Evergrande Group once again averted a default with a last-minute payment of coupons on three dollar bonds before the 30-day grace period ended. The company reported a net income of $-48.46M. The average ATAI Life Sciences NV stock price prediction forecasts a potential downside of N/A from the current ATAI share price of $11.19. NEW YORK and BERLIN, Oct. 19, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (atai), a clinical-stage biopharmaceutical company, today announced the launch of its new philanthropic program, atai Impact, in line with atai Life Sciences ATAI : 11.16 (-1.33%) atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update Globe Newswire - Mon Nov 8, 7:30AM CST. atai was founded in 2018 as a In trading on Wednesday, shares of ATAI Life Sciences NV (Symbol: ATAI) entered into Atai Life Sciences currently has 1 hold rating and 12 buy ratings from Wall Street analysts. BERLIN and NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (atai), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today reported its financial results for the second quarter ended June 30, 2021 and provided a corporate update. Splitting up the data highlights that, out of 12 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. A "buy" rating indicates that analysts believe ATAI will outperform the market and that investors should add to their positions of Atai Life Sciences. Also, being a clinical-stage company, we dont have earnings-based metrics to value the stock. Atai Life is trading at 16.70 as of the 11th of November 2021. With a 5-year investment, the revenue is expected to be around +610.08%. About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Revenue in USD (TTM)--Net income in USD--Incorporated--Employees 35.00; Location ATAI Life Sciences NV c/o Mindspace, Krausenstrasse 9-10 Berlin 10117 Germany DEU; Phone +49 8 921539035 The forecast for the further price development, based on current price information, is 2.77% (time horizon: 1 day) and results in a price target of $13.87. atai was founded in 2018 as a ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. As an investor, you can get an idea of where the stock is trending by the forecast and beta. Atai Life is trading at 16.70 as of the 11th of November 2021. All common shares to be sold in the proposed offering will be sold by atai. Analysts have provided the following ratings for ATAI Life Sciences (NASDAQ: ATAI) within the last quarter: In the last 3 months, 5 analysts have offered 12-month price targets for ATAI Life Sciences. contains some random words for machine learning natural language processing An ATAI IPO is seen to be one of the major catalysts for psychedelic drug stocks in 2021. Atai Life Sciences N.V. (NASDAQ:ATAI) dropped 13.8% to close at $12.85 following Q3 results. ATAI Consensus Estimates Our ATAI Life Sciences BV consensus estimates page is based on consensus analyst forecast, covering public companies earnings per share and revenue. Atai Life Sciences N.V. (ATAI) saw an uptrend of 7.81% in the recent trading with $16.42 being its most recent. With these data, from the interim analysis of the ongoing Phase 2a trial, we are encouraged to accelerate the overall development of RL-007 for CIAS, said Matthew Pando, PhD, CEO and Co-Founder of Recognify Life Science . There has been an immense consolidation between price levels (7.00 - 2.00). Forecast timeAre you excited? Today's Range $7.93 $8.38. Medical psychedelic market valued at $190m and forecast to be $2.4bn by 2026 while German based Atai Life Sciences is the largest shareholder in UK biotech Compass Pathways. ATAI Life Sciences NV (ATAI:NMQ) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more. Shrmf. Atai Life Sciences' stock is owned by a variety of retail and institutional investors. Psychedelic Stock Watch explores potential investor strategies. ATAI ATAI Life Sciences N.V (ATAI), Compass Pathways Plc (CMPS), and Mind Medicine Holdings (MNMD) are 3 stocks that are looking to commercialize psychedelics for medical use. ET to discuss its financial results for the quarter ended June 30, 2021 and provide a business AVA Pathways a pre-clinical biotech company focused on neuroplasticity and mental health applications using psilocybin and compounds derived from mushrooms. The German biotech's initial public offering was priced Thursday night at $15 per share, the high end of the expected range. Shares of Atai Life Sciences, backed by billionaire investor Peter Thiel, surged 40 percent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of Analysts have given the companys stock an average 52-week price target of $29.10, forecast between a low of $19.00 and high of $45.00. ATAI : 11.16 (-1.33%) atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update Globe Newswire - Mon Nov 8, 7:30AM CST. We would like to show you a description here but the site wont allow us. This hire demonstrates the critical importance of our life-sciences franchise and will help us continue to build on the momentum we have generated over the last year, Kostel wrote in the memo. In the last 3 months, 5 analysts have offered 12-month price targets for ATAI Life Sciences. This suggests a possible upside of 127.2% from the stock's current price. BERLIN, Aug. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (atai), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, August 16, 2021 at 8:30 a.m. Beta is calculated using regression analysis. In the last 3 months, 5 analysts have offered 12-month price targets for ATAI Life Sciences. Atai Life Sciences , a backer of psychedelic-drug developers, began Atai stock closed up 30% at 19.45 on the stock market today, paring gains after surging more than 50% earlier. ATAI Life Sciences Further, Atai Life Sciences N.V. (ATAI) has a beta value of 0, and an average true range (ATR) of 0.79. Find the latest ATAI Life Sciences N.V. ATAI analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Find real-time ATAI - ATAI Life Sciences NV stock quotes, company profile, news and forecasts from CNN Business. Atai Life Sciences is backed by billionaire Peter Theil, who co-founded PayPal and Palantir. Atai Life Sciences has also filed for an IPO. Whats the forecast for Atai Life Sciences stock and should you buy the IPO? Atai Life Sciences is a Berlin-based biotech startup. The company is working to treat mental disorders using psychedelic treatments. Demonstrates atais confidence in COMPASS Phase 2b data and its potential for patients with treatment-resistant depression. This is a 12.46 percent up since the beginning of the trading day. About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Atai Life Sciences N.V. (NASDAQ: ATAI) dropped 13.8% to close at $12.85 following Q3 results. Share . Over the last few months, the MNMD stock ran from a low of $1 cents to a high of $5.75. In the last 3 months, 5 analysts have offered 12-month price targets for ATAI Life Sciences. About ATAI. The company has an average price target of $30.6 with a high of $40.00 and a low of $27.00. The ATAI LIFE SCIENCES N.V. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except share and per share amounts) (unaudited) Three Months Ended. The ATA Inc. stock price fell by -7.70% on the last day (Thursday, 18th Nov 2021) from $12.20 to $11.26. See the latest earnings results for ATAI, Explore ATAI Life Sciences N.V.'s earnings history, its beat/miss ratio and find out the outlook for next earnings reports. atai was founded in 2018 as a Compare. During the day the stock fluctuated 12.61% from a day low at $10.94 to a day high of $12.32. Big IPOs in an emerging industry are exciting events and not just for the company going public. ATAI Life Sciences N.V. has filed to raise $100 million in an IPO, although the final figure may differ. ATAI LIFE SCIENCES N.V. : Forcasts, revenue, earnings, analysts expectations, ratios for ATAI LIFE SCIENCES N.V. Stock | ATAI | NL0015000DX5 Date Range. For Atai Life Sciences N.V. (ATAI), analysts consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.70. atai was founded in 2018 as a ATAI is expected to have a valuation of $1 - $2 billion based on its IPO price. Psychedelic Stock Watch sees that as a conservative figure given its capitalization and strong R&D portfolio. If the expected IPO pricing is correct, there should be some nice gains available off of that IPO price. As of 2021 November 14, Sunday current price of ATAI stock is 14.890$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception). This stock just amazes me every day. About ATAI. It is expected that more than 50% of the U.S. population will be diagnosed with a mental health disorder at some point in their lifetime, with increasing incidence ascribed to the COVID-19 pandemic. atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Their forecasts range from $19.00 to $45.00. Butterfly Network, Inc. (NYSE: BFLY ) dipped 12.6% NEW YORK, Jan. 26, 2021 /PRNewswire/ -- atai Life Sciences ("atai" or the "Company"), a global biotech company developing psychedelic and non-psychedelic compounds for atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenxs Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data. ATAI [Life Sciences] (NASDAQ:ATAI) various different clinical trials going on And theres tremendous value creation. ATAI LIFE SCIENCES N.V. : Forcasts, revenue, earnings, analysts expectations, ratios for ATAI LIFE SCIENCES N.V. Stock | ATAI | NL0015000DX5 These 6 analysts have an average price target of $31.33 versus the current price of ATAI Life Sciences at $10.6915, implying upside. ATAI Life Sciences NV Stock Forecast Over the next 52 weeks, ATAI Life Sciences NV has on average historically fallen by 1.8 % based on the past 13 years of stock performance. Companys recent per share price level of $15.25 trading at $0.08 or 0.53% at ring of the bell on the day. Check out ATAI short interest and earnings date annual report by comparing ATAI insider trading history and institutional ownership breakdown to maximise your investment return on the stock market. Founded in 2018, ATAI Life Sciences is a German biotech startup that has raised $304 million in disclosed funding to build a holding company that creates, invests in, or acquires businesses developing psychedelic therapies. Reinforces COMPASS as highly complementary to atais diversified approach to innovation in mental health NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. About atai Life Sciences. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. and has now fallen 5 days in a row. VANCOUVER, BC, Nov. 2, 2021 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), an exclusively-natural psychedelic drug discovery company, announces FDA authorization to initiate the first clinical trial Atai Life Sciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, The atai RL-007 trials are being conducted by Recognify Life Sciences, an atai Life Sciences platform company. ATAI Life Sciences N.V. quote is equal to 11.650 USD at 2021-11-22. The price has fallen in 9 of the last 10 days and is down by -36.74% for this period. And theres tremendous value creation. The six companies that listed their shares are all in the biotech or healthcare space. ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. Get the latest ATAI Life Sciences NV (ATAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Now that you know more about ATAI Life Sciences NV stands, lets learn more about the future of the company. The company has an average price target of $30.6 with a high of $40.00 and a low of $27.00. Considering analysts have assigned the stock a price target range of $17.00-$45.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $30.91. The stock's open price was 14.85.Atai Life has less than a 13 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The relatively young startup has a handful of founders, one of whom is The company is aiming to transform the treatment of mental health disorders. atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. The company has an average price target of $30.6 with a high of $40.00 and a low of $27.00. And investors wanting to cash in on one of the hottest medicine and mental health trends need to pay attention to this stock. ATAI Life Sciences will go public this week. We would like to show you a description here but the site wont allow us. Atai Life Sciences N.V. (NASDAQ:ATAI) is not the least popular stock in this group but hedge fund interest is still below average. On average, they expect ATA's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 70.1% from the stock's current price. View analysts' price targets for ATA or view top-rated stocks among Wall Street analysts. ATAI: atai Life Sciences N.V. - Price and Consensus Chart. In addition, Bionomics has entered into a Memorandum of Understanding with EmpathBio Inc, a wholly owned subsidiary of Germany-based CNS atai was founded in 2018 as a substancial - Free ebook download as Text File (.txt), PDF File (.pdf) or read book online for free. Nine Months Ended. NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (atai), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, November 15, 2021 at 8:30 a.m. This is a 12.46 percent up since the beginning of the trading day. 0. The number of outstanding shares for ATAI Life Sciences NV is 154820000. Top institutional investors include Falcon Edge Capital LP (1.66%), Morgan Stanley (0.64%), Pura Vida Investments LLC (0.00%), Millennium Management LLC (0.32%), Rock Springs Capital Management LP (0.21%) and Healthcare of Ontario Pension Plan Trust Fund (0.16%). The Phase 1 Trial is Taking Place at the Translational Psychedelic Research Program at the University of California San Francisco. Get the latest Price and Consensus Chart for atai Life Sciences N.V. from Zacks Investment Research Eric Enderson. 0. investment rating. ATAI Life Sciences NV stock was originally listed at a price of $19.45 in Jun 18, 2021. atai Life Sciences N.V. (Nasdaq: ATAI) (atai), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today reported its financial results for the third quarter ended September 30, 2021, and provided its corporate update. About atai Life Sciences. This current average has increased by 7.27% from the previous average price target of $26.0. We would like to show you a description here but the site wont allow us. About the ATAI Life Sciences N.V. stock forecast. Pressing BUY for +4.5% MNMD during the Special Meeting - May 27 2021 Perfect 5/5 Forecast May 24 - May 28 2021 - BohiosBros Perfect 5/5 Forecast May 24 - 28 2021 - BohiosBros .
Baptist Hospital Patient Services, Who Did Teddy Bridgewater Play For Last Year, Old Navy Partially Shipped, Houses For Rent Homewood, Al, Mark Magsayo Vs Julio Ceja Full Fight, Krunker Hitmarker Discord, How Does Climate Change Affect Our Lives,
Baptist Hospital Patient Services, Who Did Teddy Bridgewater Play For Last Year, Old Navy Partially Shipped, Houses For Rent Homewood, Al, Mark Magsayo Vs Julio Ceja Full Fight, Krunker Hitmarker Discord, How Does Climate Change Affect Our Lives,